Wednesday, July 8, 2026

pharma · Solid Tumor, Adult · Advanced Soft-tissue Sarcoma · MNPR

Monopar Therapeutics

Monopar Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Wilmette, USA HQ
2015 Founded
22 Employees
Public company Type
MNPR · NYSE Ticker
Company details
Status
Public
HQ
Wilmette, USA
Founded
2015
Employees
22
Programs
4
Drugs
3
Patents
3
Intelligence · Clinical Programs

Monopar Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Monopar Therapeutics.

Monopar Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Clonidine HCl Mucoadhesive Buccal Tablet

    Monopar Therapeutics

    Chemoradiotherapy-Induced Severe Oral Mucositis

    phase 3 small molecule terminated

    1 trial
  2. Camsirubicin

    Monopar Therapeutics

    Advanced Soft-tissue Sarcoma

    phase 1 small molecule terminated

    1 trial
  3. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial
  4. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Monopar Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.